{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:11Z","timestamp":1792801631187,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared with efavirenz (EFV) and superior profiles for neuropsychiatric tolerability and lipids at 48 weeks. We present data through week 96.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DRIVE-AHEAD is a phase 3, multicenter, double-blind, noninferiority trial in antiretroviral treatment-naive adults with HIV-1 RNA\u2005\u22651000 copies\/mL. Participants were randomized to a daily fixed-dose tablet of DOR (100 mg), lamivudine (3TC; 300 mg) and tenofovir disoproxil fumarate (TDF; 300 mg) (DOR\/3TC\/TDF) or EFV (600 mg), emtricitabine (FTC; 200 mg) and TDF (300 mg) (EFV\/FTC\/TDF). The efficacy end point of interest at week 96 was the proportion of participants with HIV-1 RNA\u2005levels &amp;lt;50 copies\/mL (Food and Drug Administration Snapshot Approach) with a predefined noninferiority margin of 10% to support week 48 results. Safety end points of interest included prespecified neuropsychiatric adverse events and the mean change in fasting lipids at week 96.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 734 participants randomized, 728 received study drugs and were included in analyses. At week 96, HIV-1 RNA\u2005&amp;lt;50 copies\/mL was achieved by 77.5% of DOR\/3TC\/TDF vs 73.6% of EFV\/FTC\/TDF participants, with a treatment difference of 3.8% (95% confidence interval, \u20132.4% to 10%). Virologic failure rates were low and similar across treatment arms, with no additional resistance to DOR observed between weeks 48 and 96. Prespecified neuropsychiatric adverse events and rash were less frequent in DOR\/3TC\/TDF than in EFV\/FTC\/TDF participants through week 96. At week 96, fasting low-density lipoprotein cholesterol and non\u2013high-density lipoprotein cholesterol (HDL-C) levels increased in the EFV\/FTC\/TDF group but not in the DOR\/3TC\/TDF group; the mean changes from baseline in total cholesterol\/HDL-C ratio were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02403674.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa822","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T07:10:40Z","timestamp":1602832240000},"page":"33-42","source":"Crossref","is-referenced-by-count":73,"title":["Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz\/Emtricitabine\/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial"],"prefix":"10.1093","volume":"73","author":[{"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E","family":"Squires","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania, USA"},{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"University of Paris Diderot, H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris, INSERM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Sax","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Sussmann","sequence":"additional","affiliation":[{"name":"Asistencia Cientifica de Alta Complejidad SAS, Bogota, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Kumar","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J","family":"Hanna","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Hwang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Martin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy","family":"Teppler","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"2021070111144360700_CIT0001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir Ther"},{"key":"2021070111144360700_CIT0002","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/COH.0000000000000471","article-title":"Doravirine: a review","volume":"13","author":"Colombier","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"2021070111144360700_CIT0003","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070111144360700_CIT0004","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070111144360700_CIT0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/QAI.0000000000001031","article-title":"Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants","volume":"72","author":"Smith","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021070111144360700_CIT0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","article-title":"The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects","volume":"37","author":"Behm","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2021070111144360700_CIT0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13318-018-0497-3","article-title":"Clinical pharmacokinetics and drug interactions of doravirine","volume":"43","author":"Wilby","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2021070111144360700_CIT0008","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","article-title":"Doravirine: first global approval","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"2021070111144360700_CIT0009","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2021070111144360700_CIT0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021070111144360700_CIT0011","volume-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events","author":"Division of AIDS, National Institute of Allergy and Infectious Disease","year":"2004"},{"key":"2021070111144360700_CIT0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1310\/hct1403-81","article-title":"Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine\/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies","volume":"14","author":"Nelson","year":"2013","journal-title":"HIV Clin Trials"},{"key":"2021070111144360700_CIT0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1179\/1528433614Z.0000000009","article-title":"96-week resistance analyses of the STaR study: rilpivirine\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects","volume":"16","author":"Porter","year":"2015","journal-title":"HIV Clin Trials"},{"key":"2021070111144360700_CIT0014","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40262-015-0360-5","article-title":"Comprehensive pharmacokinetic, pharmacodynamic and pharmacogenetic evaluation of once-daily efavirenz 400 and 600 mg in treatment-na\u00efve HIV-infected patients at 96 weeks: results of the ENCORE1 Study","volume":"55","author":"Dickinson","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2021070111144360700_CIT0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021070111144360700_CIT0016","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"2021070111144360700_CIT0017","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.7448\/IAS.17.4.19490","article-title":"Once-daily dolutegravir is superior to once-daily darunavir\/ritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week results from FLAMINGO","volume":"17","author":"Molina","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2021070111144360700_CIT0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2021070111144360700_CIT0019","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa822\/34970241\/ciaa822.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/1\/33\/38846441\/ciaa822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/1\/33\/38846441\/ciaa822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:41:23Z","timestamp":1625125283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/1\/33\/6041522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,18]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa822","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,18]]}}}